Invirsa
Phase 1/2Invirsa’s lead compound (INV-102), quickly and predictably augments the body’s response to DNA damage, greatly improving cell stability at the critical moment.
Founded
2016
Focus
Small Molecules
About
Invirsa’s lead compound (INV-102), quickly and predictably augments the body’s response to DNA damage, greatly improving cell stability at the critical moment.
Company Info
TypePrivate
Founded2016
LocationCambridge, United States
StagePhase 1/2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile